INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 49m ago
HOUSE PTR9m ago
SEC 13F9m ago
ROBINHOOD CHAIN9m ago
SEC FORM 4/Disposition to issuerVerified data

Giraudo Bryan reported GOSS

COO/CFO · Gossamer Bio, Inc. · Gossamer Bio, Inc. — Stock Option (Right to Buy)

Side
D
Value
—
Shares
211.5K
Price
—
Executed
Mar 19, 2026
Disclosed
Mar 20, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Mar 19 executedMar 20, 2026 disclosed

GOSS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Disposition to issuer — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · GOSS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    ND
    Nathan Steven DDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MS
    Milligan SandraDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DS
    Drynan SkyeDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CJ
    Cox Russell J.Director
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    QD
    Quisel John DDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Ciongoli Gregory AustinDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    30.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DO
    Daniel Thomas ODirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    10.0K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    PC
    Peterson CarynChief Development Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    5.80M sh
    		Aug 24, 2026Aug 26, 2026
    traded Aug 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SP
    Smith Robert Paul JRChief Commercial Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    5.80M sh
    		Aug 24, 2026Aug 26, 2026
    traded Aug 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GB
    Giraudo BryanCOO/CFO
    GOSSGossamer Bio, Inc.
    Grant or award
    		A$25K
    25 sh
    		Aug 24, 2026Aug 26, 2026
    traded Aug 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GB
    Giraudo BryanCOO/CFO
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    5.80M sh
    		Aug 24, 2026Aug 26, 2026
    traded Aug 24, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DS
    Drynan SkyeDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    115.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MS
    Milligan SandraDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    115.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    ND
    Nathan Steven DDirector
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    115.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    162.5K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    487.5K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Disposition to issuer
    		D—
    157.5K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    572.0K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Grant or award
    		A—
    562.5K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    9
    AR
    Aranda RichardChief Medical Officer
    GOSSGossamer Bio, Inc.
    Disposition to issuer
    		D—
    572.0K sh
    		Mar 19, 2026Mar 20, 2026
    traded Mar 19, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001740847-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 19, 2026
    Published
    Mar 20, 2026
    Ingested by INSIDER
    Nov 5, 04:10 UTC
    Last re-read
    Nov 5, 04:10 UTC

    Extracted facts

    Filer
    Giraudo Bryan
    Role
    COO/CFO
    Transaction
    Disposition to issuerAs filed: “D”
    Asset
    Gossamer Bio, Inc. — Stock Option (Right to Buy)
    Ticker
    GOSS
    Shares
    211.5K
    Execution date (reported)
    Mar 19, 2026
    Owned after transaction
    0 shares
    Days from execution to publication
    1

    What this establishes

    Giraudo Bryan filed this Form 4 reporting a disposition to issuer of GOSS on Mar 19, 2026. It became public on Mar 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    COO/CFO
    Giraudo Bryancik:0001740847
    Issuer
    Gossamer Bio, Inc.cik:0001728117

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.